UFP Technologies has ridden a powerful multi‑year share price climb, which puts a sharper spotlight on a basic question for you as an investor: Do the cash flows that the business can generate over time support where the stock trades today? Over the past 5 years the stock has returned 341.7%, which makes it important to check whether that kind of gain is in line with what its cash flows can justify. Recent profit growth, margin improvement and the CI Medical acquisition all feed directly...
Fresh third quarter results from UFP Technologies (UFPT) were released on 3 November. The medical packaging specialist reported higher sales of $172.43 million and net income of $20.62 million compared with a year earlier. The Q3 release has shifted attention back to UFP Technologies, with the share price jumping 17.66% on the day of the announcement to $329.82 and extending its 7 day share price return to 15.32%. That short term surge builds on a strong backdrop, with a year to date share...
Detailed price information for Hca Holdings Inc (HCA-N) from The Globe and Mail including charting and trades.
UFP Technologies Inc (UFPT) posted 11.6% sales growth and $2.88 adjusted EPS in Q3 2026, while flagging a delayed AJR offshore transfer and rising SG&A costs.
UFP Technologies stock is a "Hold" amid 12%+ organic growth, accretive M&A (CI Medical), and low leverage. Click here to learn more about UFPT.
Detailed price information for U F P Tech Inc (UFPT-Q) from The Globe and Mail including charting and trades.
UFP Technologies has seen a powerful run in its share price in recent years, which naturally raises a question for anyone looking at the stock today. Is the current valuation supported by the company’s earnings, or has sentiment moved ahead of the underlying profit stream? Over the past 5 years, UFP Technologies has delivered a total return of about 3.8x, which puts real pressure on the current earnings multiple to carry that track record forward. The business leans heavily on specialized...
Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]
Detailed price information for Cintas Corp (CTAS-Q) from The Globe and Mail including charting and trades.
Detailed price information for Insight Enterpr (NSIT-Q) from The Globe and Mail including charting and trades.
Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.
Investors need to pay close attention to UFPT stock based on the movements in the options market lately.
On August 3, UFP Technologies (NASDAQ:UFPT) reported second-quarter net income of $20.9 million, up 21.4% from $17.2 million a year earlier, alongside net sales of $174.0 million, a 15.1% jump from $151.2 million. Both figures, along with adjusted earnings per share of $2.92, marked the best quarter in the company’s history. For the six months […]
Feldmann reduced her direct stake by 18%.
UFP Technologies (NASDAQ:UFPT) outlined its strategy to expand through organic growth and acquisitions, emphasizing its role as a contract development and manufacturing organization serving medical-device companies. President and Chief Executive Officer Mitch Rock said the company provides engineer
Detailed price information for U F P Tech Inc (UFPT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Exlservice Holdings (EXLS-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.